from clinicaltrials.gov it looks like pfizer is recruiting for two phase 1 studies of PF-868554 so I would assume there's not much data on anti-viral effect yet (that makes it an easy decision, heh..)
Here's a couple of papers on ns5b inhibitors being worked on by their guys in '05. It may be worth searching through - sometimes the drug code numbers are already set in the early research literature
http://www.ncbi.nlm.nih.gov/pubmed/15863301
http://www.ncbi.nlm.nih.gov/pubmed/15911260
Also, for everyone pondering drug resistance, the following short, free access, article gives a good overview, in particular of what's been learned from HIV PIs treatment. Note the warning against "avoidance of weak sequential monotherapies".
http://jac.oxfordjournals.org/cgi/content/full/dkn175v1
sorry I meant to say 99% reduction in VL
I agree that R7128 looks really promising from the initial trial. I have been interested in it as it had a 99% VL at week 4 and 81% cleared. There was no AE to treatment and no viral mutations found. It was a small trial but promising just the same.
my doctors office called me about the Pfizer trail for PF-868554 but I can't find a whole lot of info. I told them I would like to learn a little more about it. In the meantime I am just trying to see what I can find out on my own.
I followed the pharmasset r7128 up a bit and confirmed they were only enrolling tx naive at this point. Agreed that it looks very promising.